• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Synthesis and growth-inhibitory activities of imidazo[5,1-]-1,2,3,5-tetrazine-8-carboxamides related to the anti-tumour drug temozolomide, with appended silicon, benzyl and heteromethyl groups at the 3-position.与抗肿瘤药物替莫唑胺相关的咪唑并[5,1 - ] - 1,2,3,5 - 四嗪 - 8 - 甲酰胺的合成及生长抑制活性,其在3位带有硅基、苄基和杂甲基基团。
Medchemcomm. 2018 Jan 19;9(3):545-553. doi: 10.1039/c7md00554g. eCollection 2018 Mar 1.
2
N3-substituted temozolomide analogs overcome methylguanine-DNA methyltransferase and mismatch repair precipitating apoptotic and autophagic cancer cell death.N3-取代的替莫唑胺类似物克服了甲基鸟嘌呤-DNA 甲基转移酶和错配修复,导致了凋亡和自噬性的癌细胞死亡。
Oncology. 2015;88(1):28-48. doi: 10.1159/000366131. Epub 2014 Sep 26.
3
Acridine-O-benzylguanine hybrids: Synthesis, DNA binding, MGMT inhibition and antiproliferative activity.吖啶-O-苯甲基鸟嘌呤杂合体的合成、DNA 结合、MGMT 抑制和抗增殖活性。
Eur J Med Chem. 2022 Jan 5;227:113909. doi: 10.1016/j.ejmech.2021.113909. Epub 2021 Oct 9.
4
A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells.一种 I 型联合靶向方法,用于设计针对 BRCA1/2 突变体和表达 O6-甲基鸟嘌呤-DNA 甲基转移酶(mgmt)的肿瘤细胞具有增强效力的分子。
BMC Cancer. 2017 Aug 11;17(1):540. doi: 10.1186/s12885-017-3504-1.
5
Certain imidazotetrazines escape O6-methylguanine-DNA methyltransferase and mismatch repair.某些咪唑并四嗪类化合物能够逃避 O6-甲基鸟嘌呤-DNA 甲基转移酶和错配修复。
Oncology. 2011;80(3-4):195-207. doi: 10.1159/000327837. Epub 2011 Jul 1.
6
C8-Substituted Imidazotetrazine Analogs Overcome Temozolomide Resistance by Inducing DNA Adducts and DNA Damage.C8取代的咪唑并四嗪类似物通过诱导DNA加合物和DNA损伤克服替莫唑胺耐药性。
Front Oncol. 2019 Jun 11;9:485. doi: 10.3389/fonc.2019.00485. eCollection 2019.
7
Inhibition of O6-methylguanine-DNA methyltransferase by glucose-conjugated inhibitors: comparison with nonconjugated inhibitors and effect on fotemustine and temozolomide-induced cell death.葡萄糖共轭抑制剂对O6-甲基鸟嘌呤-DNA甲基转移酶的抑制作用:与非共轭抑制剂的比较及对福莫司汀和替莫唑胺诱导细胞死亡的影响
J Pharmacol Exp Ther. 2004 Nov;311(2):585-93. doi: 10.1124/jpet.104.071316. Epub 2004 Jul 13.
8
Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide.MGMT 蛋白缺失以及 MGMT 启动子甲基化预测替莫唑胺的敏感性。
Br J Cancer. 2010 Jun 29;103(1):29-35. doi: 10.1038/sj.bjc.6605712. Epub 2010 Jun 1.
9
Repair gene O -methylguanine-DNA methyltransferase is controlled by SP1 and up-regulated by glucocorticoids, but not by temozolomide and radiation.修复基因 O-甲基鸟嘌呤-DNA 甲基转移酶受 SP1 调控,可被糖皮质激素上调,但不受替莫唑胺和辐射的影响。
J Neurochem. 2018 Jan;144(2):139-151. doi: 10.1111/jnc.14262. Epub 2018 Jan 1.
10
Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications.胶质瘤细胞系获得替莫唑胺耐药性:分子机制及潜在的转化应用。
Oncology. 2010;78(2):103-14. doi: 10.1159/000306139. Epub 2010 Mar 31.

引用本文的文献

1
In search of effective therapies to overcome resistance to Temozolomide in brain tumours.寻找克服脑肿瘤对替莫唑胺耐药性的有效疗法。
Cancer Drug Resist. 2019 Dec 19;2(4):1018-1031. doi: 10.20517/cdr.2019.64. eCollection 2019.
2
Novel Imidazotetrazine Evades Known Resistance Mechanisms and Is Effective against Temozolomide-Resistant Brain Cancer in Cell Culture.新型咪唑并四嗪可规避已知耐药机制,并在细胞培养中对替莫唑胺耐药脑肿瘤有效。
ACS Chem Biol. 2022 Feb 18;17(2):299-313. doi: 10.1021/acschembio.2c00022. Epub 2022 Feb 4.
3
C8-Substituted Imidazotetrazine Analogs Overcome Temozolomide Resistance by Inducing DNA Adducts and DNA Damage.C8取代的咪唑并四嗪类似物通过诱导DNA加合物和DNA损伤克服替莫唑胺耐药性。
Front Oncol. 2019 Jun 11;9:485. doi: 10.3389/fonc.2019.00485. eCollection 2019.

本文引用的文献

1
Temozolomide in the Era of Precision Medicine.精准医学时代的替莫唑胺
Cancer Res. 2017 Feb 15;77(4):823-826. doi: 10.1158/0008-5472.CAN-16-2983. Epub 2017 Feb 3.
2
DNA Repair Capacity in Multiple Pathways Predicts Chemoresistance in Glioblastoma Multiforme.多途径DNA修复能力预测多形性胶质母细胞瘤的化疗耐药性。
Cancer Res. 2017 Jan 1;77(1):198-206. doi: 10.1158/0008-5472.CAN-16-1151. Epub 2016 Oct 28.
3
Synthesis of [3-N-(11) C-methyl]temozolomide via in situ activation of 3-N-hydroxymethyl temozolomide and alkylation with [(11) C]methyl iodide.通过原位活化3-N-羟甲基替莫唑胺并与[¹¹C]碘甲烷进行烷基化反应合成[3-N-(¹¹C)-甲基]替莫唑胺。
J Labelled Comp Radiopharm. 2015 Mar;58(3):122-6. doi: 10.1002/jlcr.3251. Epub 2015 Feb 17.
4
N3-substituted temozolomide analogs overcome methylguanine-DNA methyltransferase and mismatch repair precipitating apoptotic and autophagic cancer cell death.N3-取代的替莫唑胺类似物克服了甲基鸟嘌呤-DNA 甲基转移酶和错配修复,导致了凋亡和自噬性的癌细胞死亡。
Oncology. 2015;88(1):28-48. doi: 10.1159/000366131. Epub 2014 Sep 26.
5
The medicinal chemistry of imidazotetrazine prodrugs.咪唑并四嗪前药的药物化学。
Pharmaceuticals (Basel). 2014 Jul 10;7(7):797-838. doi: 10.3390/ph7070797.
6
Temozolomide: mechanisms of action, repair and resistance.替莫唑胺:作用机制、修复和耐药性。
Curr Mol Pharmacol. 2012 Jan;5(1):102-14. doi: 10.2174/1874467211205010102.
7
Polymorphs and polymorphic cocrystals of temozolomide.替莫唑胺的多晶型物和多晶型共晶体。
Chem Asian J. 2008 Jul 7;3(7):1122-33. doi: 10.1002/asia.200800070.
8
MGMT gene silencing and benefit from temozolomide in glioblastoma.MGMT基因沉默与胶质母细胞瘤对替莫唑胺的获益
N Engl J Med. 2005 Mar 10;352(10):997-1003. doi: 10.1056/NEJMoa043331.
9
Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.临床试验证实了O-6-甲基鸟嘌呤-DNA甲基转移酶启动子甲基化在接受替莫唑胺治疗的胶质母细胞瘤患者中的预测价值。
Clin Cancer Res. 2004 Mar 15;10(6):1871-4. doi: 10.1158/1078-0432.ccr-03-0384.
10
Resistance-modifying agents. 8. Inhibition of O(6)-alkylguanine-DNA alkyltransferase by O(6)-alkenyl-, O(6)-cycloalkenyl-, and O(6)-(2-oxoalkyl)guanines and potentiation of temozolomide cytotoxicity in vitro by O(6)-(1-cyclopentenylmethyl)guanine.耐药性修饰剂。8. O(6)-烯基、O(6)-环烯基和O(6)-(2-氧代烷基)鸟嘌呤对O(6)-烷基鸟嘌呤-DNA烷基转移酶的抑制作用以及O(6)-(1-环戊烯基甲基)鸟嘌呤对替莫唑胺体外细胞毒性的增强作用。
J Med Chem. 2000 Nov 2;43(22):4071-83. doi: 10.1021/jm000961o.

与抗肿瘤药物替莫唑胺相关的咪唑并[5,1 - ] - 1,2,3,5 - 四嗪 - 8 - 甲酰胺的合成及生长抑制活性,其在3位带有硅基、苄基和杂甲基基团。

Synthesis and growth-inhibitory activities of imidazo[5,1-]-1,2,3,5-tetrazine-8-carboxamides related to the anti-tumour drug temozolomide, with appended silicon, benzyl and heteromethyl groups at the 3-position.

作者信息

Cousin David, Hummersone Marc G, Bradshaw Tracey D, Zhang Jihong, Moody Christopher J, Foreiter Magdalena B, Summers Helen S, Lewis William, Wheelhouse Richard T, Stevens Malcolm F G

机构信息

Pharminox Ltd , Biocity , Pennyfoot St. , Nottingham NG1 1GF , UK.

School of Pharmacy , University of Nottingham , NG7 2RD , UK . Email:

出版信息

Medchemcomm. 2018 Jan 19;9(3):545-553. doi: 10.1039/c7md00554g. eCollection 2018 Mar 1.

DOI:10.1039/c7md00554g
PMID:30108945
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6072467/
Abstract

A series of 3-(benzyl-substituted)-imidazo[5,1-]-1,2,3,5-tetrazines () and related derivatives with 3-heteromethyl groups has been synthesised and screened for growth-inhibitory activity against two pairs of glioma cell lines with temozolomide-sensitive and -resistant phenotypes dependent on the absence/presence of the DNA repair protein -methylguanine-DNA methyltransferase (MGMT). In general the compounds had low inhibitory activity with GI values >50 μM against both sets of cell lines. Two silicon-containing derivatives, the TMS-methylimidazotetrazine () and the SEM-analogue (), showed interesting differences: compound () had a profile very similar to that of temozolomide with the MGMT+ cell lines being 5 to 10-fold more resistant than MGMT- isogenic partners; the SEM-substituted compound () showed potency across all cell lines irrespective of their MGMT status.

摘要

一系列3-(苄基取代)-咪唑并[5,1-]-1,2,3,5-四嗪()以及具有3-杂甲基的相关衍生物已被合成,并针对两对具有对替莫唑胺敏感和耐药表型的胶质瘤细胞系进行了生长抑制活性筛选,这些表型取决于DNA修复蛋白O6-甲基鸟嘌呤-DNA甲基转移酶(MGMT)的缺失/存在。总体而言,这些化合物对两组细胞系的抑制活性较低,GI值>50μM。两种含硅衍生物,即TMS-甲基咪唑并四嗪()和SEM类似物(),表现出有趣的差异:化合物()的情况与替莫唑胺非常相似,MGMT+细胞系比MGMT-同基因配对细胞系耐药5至10倍;SEM取代的化合物()在所有细胞系中均显示出活性,无论其MGMT状态如何。